Navigation Links
Yale researchers identify targets for immunotherapy in early-stage breast cancer
Date:7/18/2014

July 17, 2014, New Haven, CT Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials. The findings were published in the Journal of Clinical Cancer Research in May.

PD-L1 is a protein that plays an important role in suppressing immune response, and in cancer, it may allow tumors to evade immune attack. The study demonstrated that about 60 percent of early-stage breast cancers have PD-L1 expression, and a subset of these cancers also have large numbers of tumor infiltrating lymphocytes. High levels of lymphocytes and PD-L1 predicted for better survival, suggesting a beneficial role for the immune system in at least partially controlling these cancers.

"This is exciting because these findings provide the rationale to test PD-L1 targeted therapies in breast cancer with the hope of further improving cure rates in early stage breast cancer," said Lajos Pusztai, MD, DPhil, professor of Medical Oncology and chief of Breast Medical Oncology at Smilow Cancer Hospital, Yale Cancer Center, and an author on the study. "Patients with many tumor infiltrating lymphocytes and high PD-L1 expression may be the ideal candidates for these therapies."

The in situ mRNA detection method used in the study, eliminates many of the technical problems that older immunohistochemistry assays had, Pusztai added.


'/>"/>

Contact: Vicky Agnew
vicky.agnew@yale.edu
203-785-7001
Yale University
Source:Eurekalert

Page: 1

Related biology news :

1. CNIO researchers discover a gene that links stem cells, aging and cancer
2. Duck migration study reveals importance of conserving wetlands, MU researchers find
3. Researchers advance understanding in immune response to infectious disease
4. Researchers find organic pollutants not factor in turtle tumor disease
5. Largest International Meeting for the Study of Reproductive Biology Attracts Researchers from 36 Countries in Grand Rapids, Michigan
6. Little too late: Researchers identify disease that may have plagued 700-year-old skeleton
7. Researchers declassify dinosaurs as being the great-great-grandparents of birds
8. IPCC must consider alternate policy views, researchers say
9. Science and cookies: Researchers tap into citizen science to shed light on ant diversity
10. Researchers receive $12.6 million NIH grant to study genetics of Alzheimers
11. Researchers uncover new knowledge about our intestines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... Dana-Farber Cancer Institute researchers have identified a molecular mechanism ... how consuming foods rich in saturated fats and trans-fatty ... and increases one's risk of heart disease and certain ... scientists led by Bruce Spiegelman, PhD, report that the ...
... patients with high-risk breast cancer treated with radical mastectomy ... to better survival outcomes with few long-term toxic effects, ... which appears in the January 19 issue of the ... Columbia randomized radiation therapy trial was designed to determine ...
... recent U.S. study, investigators in Japan found no association ... of high blood pressure, as reported in the March ... available online. , The researchers reported that they were ... known as the Kaposi's sarcoma virus, in the lungs ...
Cached Biology News:Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 2Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 3Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down 2Association of herpesvirus with lung disorder questioned 2
(Date:4/23/2015)... , April 23, 2015  Propanc Health Group ... company, focuses on the development of cancer treatments ... company lead product includes PRP, a patented formulation ... chymotrypsinogen, as well as the enzyme amylase designed ... developing a combination of anti-cancer agents working in ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company focused ... Patent and Trademark Office has issued 2 new patents ... US Pat. No. 8,986,727 was issued on March 24, ... for the sustained release of therapeutic agents. The ... (zero-order) release of large and small molecules for several ...
(Date:4/22/2015)... 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced that ... 2015 on Thursday, May 7, 2015 after the close ... and conference call for 4.30 pm ET (1.30 pm ... audio of the conference call will be webcast over ... of the news media and the general public. To ...
(Date:4/22/2015)... Calif. , April 22, 2015 ... and analytics, announced today that it has opened ... its continued growth and expansion.  The common stock ... Act, Section 506(c), a law intended to encourage ... regulations.  Prior to 506(c), small businesses largely relied ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Wis. - Lucigen Corp . and ... giving Lucigen exclusive worldwide rights to manufacture and sell ... , ,Under the agreement, Imaxio will retain the right ... applications, but Lucigen will provide the cells to commercial ...
... - It has yet to turn a profit, and it ... scope, but the decision by Madison research tool manufacturer NimbleGen ... to $75 million is the latest bit of evidence that the ... continues a pattern of growth and visibility for NimbleGen, which ...
... Alfalight , a manufacturer of high-power diode lasers, has ... million from the U.S. Army Research Laboratory . ... suitable for pumping high-power, fiber-laser systems, developed in conjunction ... commercial products. , ,Manoj Kanskar, vice president of research ...
Cached Biology Technology:Lucigen Corp. enters global licensing agreement 2IPO-bound NimbleGen traveling in fast company 2IPO-bound NimbleGen traveling in fast company 3IPO-bound NimbleGen traveling in fast company 4
Yersinia pestis...
... The features we add to WinList come ... product every day. Features like automatic region ... the result of good suggestions, thoughtful conversations, ... the features you depend on are still ...
Insect Cell Lysis Buffer 50 ml...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Biology Products: